Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II data presented for NS-0200 in obesity

June 12, 2019

Deciphera adds first-in-class autophagy inhibitor to pipeline

June 12, 2019

Clinical data show potential for improved renal transplant outcomes with CFZ-533

June 12, 2019

Preliminary results from phase I study of MORAb-202 in patients with FRA-positive solid tumors

June 12, 2019

First-in-human data presented for the nanotherapeutic compound NU-0129

June 12, 2019

Clogged (nuclear) pores lead to febrile encephalopathy

June 12, 2019

Bacteriophages have "cascading effects" on microbiome

June 12, 2019

A specific CNOT1 mutation results in impaired pancreatic and neurological development

June 12, 2019

Tree SLIT-tablet against allergic rhinitis approved in Europe

June 11, 2019

PPC-06 meets both coprimary endpoints in phase IIb study in plaque psoriasis

June 11, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.